



(51) International Patent Classification:
C07D 417/14 (2006.01) **A61P 3/10** (2006.01)
A61K 31/427 (2006.01)

(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei
Osaka Midotsuji Bldg., 1-1, Fushimimachi 4-chome,
Chuo-ku, Osaka-shi, Osaka, 5410044 (JP).

(21) International Application Number:
PCT/JP2009/057625

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,
SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:
9 April 2009 (09.04.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2008-102691 10 April 2008 (10.04.2008) JP

(71) Applicant (for all designated States except US): **TAKE-
DA PHARMACEUTICAL COMPANY LIMITED**
[JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi,
Osaka, 5410045 (JP).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **YASUMA, Tsuneo**
[JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPAN-
Y LIMITED, 17-85, Jusohonmachi 2-chome, Yo-
dogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **TAKAKU-
RA, Nobuyuki** [JP/JP]; c/o TAKEDA PHARMACEUTI-
CAL COMPANY LIMITED, 17-85, Jusohonmachi 2-
chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: FUSED RING COMPOUNDS AND USE THEREOF



(57) Abstract: The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.